AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value

With Euro Area consumer confidence improving and inflation expectations easing, investors are again paying attention to what they are paying for each stream of future cash flow. This is where undervalued cash flow stocks come into focus. When prices lag behind fair value estimates based on cash flows, patient investors can find mispriced opportunities. This article highlights three stocks from the Undervalued Stocks Based On Cash Flows screener that are worth a closer look.

The three stocks below are a starting sample, while the full screen surfaced 44 more companies with cash flow profiles and valuation stories that may be just as compelling. To map out those ideas in detail, head straight into the Undervalued Stocks Based On Cash Flows screener to identify and analyze the highest conviction candidates.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company that develops and sells prescription medicines, with a major focus on oncology drugs such as Tagrisso, Imfinzi, Enhertu and Lynparza that provide recurring cash flows, alongside broader portfolios in cardiovascular, renal and metabolism, respiratory, vaccines and rare diseases.

Operations: AstraZeneca generates its revenue primarily from pharmaceuticals, with about $61.4 billion reported from this segment.

Market Cap: £189.8 billion

AstraZeneca is worth a closer look for investors who prioritize cash flow backed value rather than just headlines. The oncology portfolio, including Tagrisso, Imfinzi, Enhertu and Lynparza, is a key driver behind the discounted cash flow case. A broader pipeline in vaccines, CVRM and rare diseases helps support resilience. Earnings growth, higher profit margins and strong Return on Equity indicate that current cash generation is already robust, yet the stock is flagged as trading below a DCF based fair value estimate. The risk side is significant, with high R&D spend, pricing pressure and heavy reliance on several blockbuster drugs. Recent oncology trial wins and new approvals indicate that there may be additional aspects to AstraZeneca’s cash flow profile beyond what is reflected in the current share price.

AstraZeneca’s cash rich oncology engine and wider pipeline may be masking what investors are really paying for future cash flows. Get the full picture in the DCF valuation analysis for AstraZeneca to see what the market might be missing.

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is an infrastructure and private equity manager that focuses on renewable energy projects such as solar, onshore wind and battery storage, earning long term fees and energy related revenues from the assets it manages while also running private equity, venture capital and listed funds for institutional and retail clients across the UK, Europe and Australia.

Operations: Foresight generates most of its revenue from Real Assets at about £114.8 million, with £50.1 million coming from its Private Equity segment.

Market Cap: £553.4 million

Foresight Group Holdings may appeal to investors who are interested in recurring cash flows backed by real assets rather than purely market driven trading income. Its renewable infrastructure platform links fee income and energy management revenues to long term solar, wind and storage projects, and recent results show £164.9 million of revenue and £42.8 million of net income that relate to this cash generation profile. The stock is also described as trading below an SWS DCF based fair value, while management is using buybacks and new higher fee products to reshape earnings per share. A key consideration is that funding relies on external borrowings, which makes returns sensitive to financing costs and regulation in its core UK and European markets. Any potential upside in Foresight’s cash flow profile therefore needs to be weighed against these risks.

Foresight Group Holdings links long term real asset cash flows with a stock that is still priced for hesitation. See how that gap shows up in the DCF valuation analysis for Foresight Group Holdings and what the fee mix hints at next.

BAE Systems (LSE:BA.)

Overview: BAE Systems is a global defense and aerospace company that supplies combat vehicles, weapons, munitions, aircraft, ships and electronic systems, backed by long term support and maintenance contracts for government and military customers. Its Platforms & Services segment, which produces combat vehicles and munitions and runs naval repair programs, is a key source of recurring cash flows that links directly to the undervalued cash flow theme of this screener.

Operations: BAE Systems generates revenue across Electronic Systems (£7.8b), Air (£7.7b), Maritime (£6.7b), Platforms & Services (£5.3b) and Cyber & Intelligence (£2.4b), with only a small offset from intra group sales.

Market Cap: £60.2b

Investors looking at BAE Systems for this cash flow focused screener are effectively assessing what they might be missing in a business where multi year defense contracts and a £75b order backlog provide a high degree of visibility on future work. The Platforms & Services segment is central here, with combat vehicles, munitions and naval service work tied to long term agreements that can support discounted cash flow analysis. On the other side of the ledger, there are material risks related to ESG pushback, dependence on large government contracts and recent regulatory scrutiny such as the US export control fine announced in August 2026. The interaction between that revenue visibility and those pressures is what makes BAE a candidate for closer attention.

BAE Systems has long term contracts and a £75b order backlog that many investors track; yet the real story may be how future cash flows stack up against current expectations in the DCF valuation analysis for BAE Systems

Seeking Alternatives Before The Crowd?

Fresh ideas often move first, and the strongest breakout momentum can be caught only while it matters. Do not wait until every stock is flying. Act now and get in early.

• Spot steady income potential by scanning companies in the 6 dividend fortresses before yields change and the strongest payers move further out of reach.
• Review the curated 37 robotics and automation stocks to consider early momentum in automation while these themes are still under the radar for now.
• Review hand picked stocks in the 39 power grid technology and infrastructure stocks to evaluate potential infrastructure ideas before capital chases the same opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com